

**Remarks/Arguments**

Applicants have amended the specification to provide the priority claim. The claims have been amended to remove multiple dependencies and to otherwise place the claims in an appropriate U.S. format.

Specifically:

- Claim 1 has been put into proper US language using the language from claim 17 (now cancelled).
- The definition of a compound of formula (I) has been incorporated into claim 2.
- Claims 12 and 13 have been made dependent on claim 2.
- Certain typographical errors have been amended.

No new matter has been added by these amendments.

The above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 101401-1P US.

Respectfully submitted,  
/Lucy Padget/

---

Name: Lucy Padget  
Dated: 17<sup>th</sup> August 2006  
Reg. No.: L0074  
Phone No.: 781-839-4182  
Global Intellectual Property, Patents,  
AstraZeneca R&D Boston,  
35, Gatehouse Drive,  
Waltham,  
MA 02451